Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron Versus Oxybutynin After Posterior Urethral Valve Ablation
NCT07668232Completed
- Sponsor
- South Valley University
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Randomised trial of mirabegron in Posterior urethral valves (PUV) (2 arms), sponsored by South Valley University. Primary endpoints: Efficacy of Mirabegron and Oxybutynin on upper and lower urinary tract at 6 months, Safety of Mirabegron usage after posterior urethral valve ablation by measuring arterial blood pressure at 6 months and 1 more. Started Jan 2025; status: completed.
02
Drugs
mirabegron
03
Conditions
Posterior urethral valves (PUV)
Beyond the preview
Go deeper on NCT07668232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668232.